Get the Stockscreener App
14.06
5.00%
-0.74
After Hours:
14.23
0.17
+1.21%
Bicara Therapeutics Inc stock is traded at $14.06, with a volume of 395.73K.
It is down -5.00% in the last 24 hours and down -19.33% over the past month.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
See More
Previous Close:
$14.80
Open:
$14.71
24h Volume:
395.73K
Relative Volume:
0.72
Market Cap:
$770.23M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-6.89%
1M Performance:
-19.33%
6M Performance:
+34.29%
1Y Performance:
+6.35%
1-Day Range:
$13.80
$15.06
1-Week Range:
$13.80
$16.00
52-Week Range:
$7.80
$19.71
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Name
Bicara Therapeutics Inc
Sector
Industry
Phone
617-468-4219
Address
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
14.06 | 810.77M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-26 | Initiated | Citizens JMP | Mkt Perform |
| Jan-08-26 | Initiated | BTIG Research | Buy |
| Dec-18-25 | Initiated | Mizuho | Neutral |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| May-23-25 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Apr-17-25 | Initiated | Wells Fargo | Underweight |
| Feb-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
| Oct-08-24 | Initiated | Stifel | Buy |
| Oct-08-24 | Initiated | TD Cowen | Buy |
View All
Bicara Therapeutics Inc Stock (BCAX) Latest News
FMR LLC's Strategic Acquisition of Bicara Therapeutics Inc Shares - GuruFocus
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Published on: 2026-02-04 16:21:43 - baoquankhu1.vn
Aug Technicals: Why is Bicara Therapeutics Inc stock going downTrade Risk Assessment & Fast Entry Momentum Alerts - baoquankhu1.vn
Aug Breakouts: Why is Bicara Therapeutics Inc stock going downWeekly Investment Report & Consistent Growth Stock Picks - baoquankhu1.vn
Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Citizens Initiates Coverage of Bicara Therapeutics (BCAX) with Market Outperform Recommendation - Nasdaq
Bicara Therapeutics (NASDAQ:BCAX) Now Covered by Citizens Jmp - MarketBeat
Citizens initiates coverage on Bicara Therapeutics stock with Market Outperform rating By Investing.com - Investing.com Nigeria
Citizens initiates coverage on Bicara Therapeutics stock with Market Outperform rating - Investing.com Canada
Ivan Hyep Sells 1,882 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - Defense World
Hyep Ivan, CFO of Bicara Therapeutics, sells $34,162 in BCAX stock - Investing.com Canada
Ryan Cohlhepp Sells 3,828 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - MarketBeat
Stocks showing improving market leadership: Bicara Therapeutics earns 82 RS rating - MSN
Bicara Therapeutics (BCAX) Investor Outlook: A 74.97% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Analyst Upgrade: Should I set a stop loss on Bicara Therapeutics IncOptions Play & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Stocks To Watch: Bicara Therapeutics Sees Relative Strength Rating Rise To 81 - Investor's Business Daily
Quarterly Earnings: What are analysts price targets for Bicara Therapeutics IncVolume Spike & Real-Time Buy Signal Alerts - baoquankhu1.vn
BCAX: De-Risked FORTIFI-HN01 Path, Differentiated Ficera Profile, and Solid Cash Runway Underpin Buy Rating and $28 Target - TipRanks
Bicara Therapeutics Inc. (BCAX) Investor Outlook: Exploring an 84% Potential Upside in Biotechnology - DirectorsTalk Interviews
Bicara Therapeutics stock maintains Buy rating at BTIG on clinical progress - Investing.com Nigeria
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicara Therapeutics Inc. (BCAX), NewAmsterdam Pharma Company (NAMS) and GE Healthcare Technologies Inc (GEHC) - The Globe and Mail
Does Bicara Therapeutics Inc align with a passive investing strategyDividend Hike & Weekly Market Pulse Updates - baoquankhu1.vn
H.C. Wainwright reiterates Buy rating on Bicara Therapeutics stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on Bicara Therapeutics stock - Investing.com
How cyclical is Bicara Therapeutics Inc.’s revenue stream2025 Market Outlook & Daily Growth Stock Investment Tips - Bollywood Helpline
Bicara Therapeutics (NASDAQ:BCAX) Given Outperform Rating at Wedbush - Defense World
Growth Report: Will Bicara Therapeutics Inc. stock continue upward momentumJuly 2025 Opening Moves & Weekly Breakout Watchlists - Bộ Nội Vụ
Wedbush Reaffirms Outperform Rating for Bicara Therapeutics (NASDAQ:BCAX) - MarketBeat
Bicara selects optimal dose for head and neck cancer drug in pivotal study - Investing.com Nigeria
Bicara Therapeutics Touts Breakthrough Ficerafusp Data, Picks 1,500 mg Dose for FORTIFY-HNS Trial - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 7%Time to Sell? - MarketBeat
BCAX: Ficerafusp alfa shows deep, durable responses and blockbuster potential in head and neck cancer - TradingView
Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook - Sahm
Bicara Sets Phase 3 Path for Ficerafusp Alfa - TipRanks
Bicara Therapeutics announces phase 3 optimal dose and provides 2026 corporate outlook - marketscreener.com
Bicara Therapeutics Inc Announces Phase 3 Optimal Dose and 2026 Outlook - TradingView
Bicara Therapeutics Announces Phase 3 Optimal Dose And Provides 2026 Corporate Outlook - TradingView
Published on: 2026-01-12 06:24:33 - moha.gov.vn
Bicara Therapeutics (NASDAQ:BCAX) Trading 7.8% Higher – Should You Buy? - Defense World
Is Bicara Therapeutics Inc. stock trading at a premium valuationWeekly Trade Review & Precise Trade Entry Recommendations - ulpravda.ru
BTIG Research Begins Coverage on Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Inc.Common Stock (NQ: BCAX - FinancialContent
Bicara Therapeutics (NASDAQ:BCAX) Trading Up 7.8%Here's Why - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Upgraded to "Strong-Buy" at BTIG Research - MarketBeat
Published on: 2026-01-09 02:43:58 - Улправда
Is Bicara Therapeutics Inc. stock a defensive play in 2025July 2025 Breakouts & Safe Entry Trade Signal Reports - Улправда
Bicara Therapeutics Inc Stock (BCAX) Financials Data
There is no financial data for Bicara Therapeutics Inc (BCAX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):